DNTH Reports $719M Gross Proceeds, $1.2B Cash, Orphan Drug Designation for Claseprubart in Myasthenia Gravis, Phase 3 gMG Trial On Track for Mid-2026 Initiation, Top-Line Results Expected 2H’28, Phase 2 MoMeNtum Ongoing, Phase 1 DNTH212 Data Anticipated 2H’26, Building Rheumatolo
Dianthus Therapeutics, Inc. Common Stock · PHARMACEUTICAL PREPARATIONS · Now $89.45
-9.7% since the alert
$90.24 → $81.52
Get alerts like this in real time
Push notifications the moment a signal fires. No spam, no crypto, no fluff.
Download for iOS